Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : FrontFundr
Deal Size : $1.0 million
Deal Type : Funding
Details : With no treatments currently available, Oak Bay Biosciences ‘Lead Molecule’ could be more than 90% effective in preventing the retinal cell death associated with Stargardt disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 29, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : FrontFundr
Deal Size : $1.0 million
Deal Type : Funding